NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Sanofi
Conditions: Dermatitis Atopic
Interventions: Lunsekimig, Placebo
Countries: United States, Czechia, Japan, Poland
This is a parallel, Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of lunsekimig monotherapy in adult participants (aged 18 to 80 years, inclusive) with moderate-to-severe atopic dermatitis (AD). This study explores the efficacy and safety of 3 subcutaneous (SC) dose regimens of lunsekimig in adult participants with moderate-to-severe AD who have a documented history, within 6 months prior to baseline, of an inadequate response to topical treatments or for whom topical therapies are not advised. The study consists of 6 arms: 3 parallel dosing regimens and matching placebo arms. Additionally, participants have the option of engaging in a dense pharmacokinetic/pharmodynamic (PK/PD) sampling subgroup. The study duration will be up to approximately 36 weeks, including up to 4 weeks of screening, 24 weeks of treatment period and an 8-week safety follow-up period.
Sex: ALL
Age: 18 Years to 80 Years
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * Participants must be 18 to 80 years of age, inclusive, at the time of signing the informed consent. * Diagnosis of Atopic Dermatitis (AD) as defined by the American Academy of Dermatology (AAD) clinical guidelines (2023) for 1 year or longer at baseline (Day 1) * Documented history within 6 months prior to Screening Visit, of either inadequate response or inadvisability of topical treatments * Eczema Area and Severity Index (EASI) score of 16 or higher (range, 0 to 72) at baseline (Day 1) * Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) score of 3 or 4 at baseline visit (Day 1) (on the 0 to 4 vIGA-AD scale, a vIGA-AD score of 3 and 4 represents moderate and severe, respectively). * AD involvement of 10% or more of Body Surface Are (BSA) at baseline (Day 1) * Weekly average of daily Peak Pruritis-Numerical Rating (PP-NRS) score of ≥4 at baseline (Day 1) * Must have applied a stable dose of topical bland emollient (simple moisturizer, no additives \[eg, urea\]) at least once daily for a minimum of 5 out of 7 consecutive days before baseline (Day 1). Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: * Skin comorbidity that would adversely affect the ability to undertake AD assessments (eg, psoriasis, tinea corporis, and lupus erythematosus) according to the Investigator's judgment. * Known history of, or suspected, significant current immunosuppression NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
- Encino, California, United States
- Sacramento, California, United States
- Thousand Oaks, California, United States
- Boca Raton, Florida, United States
- Coral Gables, Florida, United States
- Evans, Georgia, United States
- Boise, Idaho, United States
- New Albany, Indiana, United States
- Plainfield, Indiana, United States
- Plainfield, Indiana, United States
- West Lafayette, Indiana, United States
- Louisville, Kentucky, United States
- Covington, Louisiana, United States
- Quincy, Massachusetts, United States
- Troy, Michigan, United States
- Saint Joseph, Missouri, United States
- Reno, Nevada, United States
- New York, New York, United States
- Fargo, North Dakota, United States
- Rapid City, South Dakota, United States
- Austin, Texas, United States
- San Antonio, Texas, United States
- Burien, Washington, United States
- Prague, Czechia
- Prague, Czechia
- Prague, Czechia
- Prague, Czechia
- Asahikawa-shi, Japan
- Fukuoka, Japan
- Kofu, Japan
- + 22 more on CT.gov